Compound Screening TRIZ Cases

Amino acid modifications resolve low solubility and short half-life, enabling high throughput screening.

Binding inhibitors block activin and ACVR1 interaction, resolving the contradiction between managing flare-ups and inhibiting ectopic ossification progression.

Topical EZH2 inhibitors suppress IκBζ expression, reducing systemic side effects and therapy resistance compared to monoclonal antibodies.

Monoclonal antibodies bind MDL-1 to prevent Galectin-9 interaction, reducing DAP12 phosphorylation and inflammation without broad toxicity.

Non-specific surface binding assays with signaling agents reduce antimicrobial susceptibility testing time below four hours while maintaining accuracy.

Assay lysozyme and cathepsin S levels in blood samples to detect neurodegeneration risk using specific enzyme biomarkers.

CRBN protein drives neural stem cell differentiation to address the lack of effective factors for cerebral cortex disease treatment.

Screening against the T1R1/T1R3 receptor discovers kokumi enhancers, reducing glutamate concentration in food products.

Truncated interleukin-38 targets IL-1RAPL1 to inhibit JNK signaling and TH17 generation, resolving side effects from broad immunosuppression.

Human monoclonal antibody detects CD26 protein via specific epitope binding.

ABHD5 and HDAC4-NT variants inhibit proteolytic cleavage, preventing myocardial remodeling and reducing cardiac dysrhythmia risk.

Thermal denaturation of unbound chimeric proteins enables sensitive ligand detection without centrifugation or fluorescence interference.

Amphiphilic polymers stabilize droplet-interface bilayers, enabling prolonged ion channel recordings without complex cell-based instrumentation.

Computational methods rank tumor neoantigens by MHC binding and expression to guide synthetic mRNA vaccine production.

Detect mutant BAP1 or reduced wild-type protein levels to identify cancer cells sensitive to death receptor ligand therapy.

Genetically engineered FRET biosensors detect tau protein conformational changes via fluorescence lifetime shifts to identify modulating compounds.

Hepatocyte preparations measure bile salt export transport activity using liquid chromatography mass spectrometry detection.

Screening TAS2R46 receptor-expressing cells identifies agents that modulate dextromethorphan binding activity.

SUSD2 protein isolates pancreatic endocrine progenitor cells, resolving low differentiation efficiency in stem cell therapies.

PirB antagonists block myelin-associated inhibition to enhance neuronal regeneration.

Engineered p27 resolves active form generation challenges by forming stable trimeric complexes with Cdk4 and cyclin D.

Heat-resistant protease cleaves proteins at elevated temperatures to accelerate structural analysis workflows.

Glp-Asn-Pro-D-Tyr-DTrp-NH2 binds selectively to human CNS TRH receptors.

Comparing baseline and follow-up CDK4 and CDK6 activity values against thresholds to predict inhibitor sensitivity and monitor resistance development.

Non-glycated native high-density lipoproteins deliver superior coronavirus killing activity, addressing the lack of curative treatments for SARS-CoV-2.

Segmenting IgG subclasses into distinct measurements resolves the contradiction between prediction accuracy and system complexity for WT1 peptide immunotherapy.

BH3 profiling detects mitochondrial membrane permeabilization to predict chemotoxicity and avoid adverse patient responses.

Exosomal protein expression analysis determines lung cancer aggressiveness, avoiding invasive biopsy injury while maintaining prognostic accuracy.

Targeting specific PRRG4 and PRRG2 proteins improves early cancer detection accuracy while managing diagnostic method complexity.

Culturing excised human skin under controlled conditions preserves barrier function and cellular composition, reducing false positives in screening assays.

A pharmaceutical composition uses siRNA to inhibit target proteins and reduce collagen levels in scar tissue.

Multi-dimensional fluorescence spectrum measurement determines fluid composition and well connectivity in situ, eliminating sample transportation delays.

A cell-free system using 3 to 5 percent wheat germ extract enables robust protein synthesis and viral capsid assembly.

Presenilin binding polypeptides block specific presenilin interactions to decrease beta-amyloid production and delay Alzheimer's onset.

Inhibiting BX648577 gene expression treats leukemia and identifies susceptible patients through TIHL protein quantification.

DNA display libraries screen binding polypeptides against native cell-surface antigens, preserving conformational epitopes lost during solubilization.

Measuring aryl hydrocarbon receptor ligands in patient samples predicts immune checkpoint inhibitor responsiveness, enabling targeted AhR antagonist treatment.

Targeting domain 2 of LAG-3 with monoclonal antibodies disrupts receptor dimerization, resolving insufficient clinical efficacy from domain 1 therapies.

Automated image analysis of fluorescent ring patterns enables robust high-throughput screening of bitter blockers and sweet molecules.

Measuring anoctamin expression levels enables accurate determination of absorbed ionizing radiation doses and early diagnosis of radiation toxicity.

A CRISPR-Cas9 plasmid integrates EGFP into HCT116 cells via electroporation to create a stable reporter line.

Analyzing CLEC1B gene single nucleotide polymorphisms identifies cardiovascular risk through genetic markers in biological samples.

Antibody-based detection of dynactin subunit p62 in blood overcomes the precision trade-off of cerebrospinal fluid analysis for routine screening.

Antibodies target BST1 expression to kill cancer cells while sparing normal tissue from toxicity.

TL1A agonists stimulate IL-22 production via mononuclear phagocytes.

A lens-free device integrates optical detection and microelectrode arrays for simultaneous cellular signal analysis.

Cleaving denatured HLAs with serine proteases to distinguish native antibodies and reduce false positives in transplant matching.

Fluorescence resonance energy transfer detects compound binding to cereblon, resolving low sensitivity in traditional affinity assays.